There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adaptimmune Therapeutics (NASDAQ:ADAP) and Nucana Plc (NASDAQ:NCNA) with bullish sentiments.
Adaptimmune Therapeutics (ADAP)
In a report released today, Reni Benjamin from Raymond James maintained a Buy rating on Adaptimmune Therapeutics, with a price target of $16. The company’s shares closed on Friday at $10.76.
Benjamin commented:
“We are maintaining our Outperform rating for Adaptimmune but lowering our target to $16 (previously was $20). Oncology (ESMO), Adaptimmune reported results from the wholly owned MAGE-A10 and MAGE-A4 SPEAR T-cell Phase I/II studies.”
According to TipRanks.com, Benjamin is a 1-star analyst with an average return of -0.9% and a 37.2% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences Inc, Asterias Biotherapeutics, and Audentes Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptimmune Therapeutics with a $18 average price target.
See today’s analyst top recommended stocks >>
Nucana Plc (NCNA)
Cowen & Co. analyst Boris Peaker maintained a Buy rating on Nucana Plc today. The company’s shares closed on Friday at $20.30.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 8.6% and a 41.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nucana Plc.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
